These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 8653993)
1. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Skjelbo E; Mutabingwa TK; Bygbjerg Ib; Nielsen KK; Gram LF; Brøosen K Clin Pharmacol Ther; 1996 Mar; 59(3):304-11. PubMed ID: 8653993 [TBL] [Abstract][Full Text] [Related]
2. Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. Herrlin K; Massele AY; Rimoy G; Alm C; Rais M; Ericsson O; Bertilsson L; Gustafsson LL Clin Pharmacol Ther; 2000 Aug; 68(2):189-98. PubMed ID: 10976550 [TBL] [Abstract][Full Text] [Related]
3. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Funck-Brentano C; Bosco O; Jacqz-Aigrain E; Keundjian A; Jaillon P Clin Pharmacol Ther; 1992 May; 51(5):507-12. PubMed ID: 1587064 [TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Jeppesen U; Rasmussen BB; Brøsen K Clin Pharmacol Ther; 1997 Sep; 62(3):279-86. PubMed ID: 9333103 [TBL] [Abstract][Full Text] [Related]
5. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698 [TBL] [Abstract][Full Text] [Related]
6. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613 [TBL] [Abstract][Full Text] [Related]
7. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796 [TBL] [Abstract][Full Text] [Related]
8. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Basci NE; Bozkurt A; Kortunay S; Isimer A; Sayal A; Kayaalp SO Br J Clin Pharmacol; 1996 Dec; 42(6):771-3. PubMed ID: 8971434 [TBL] [Abstract][Full Text] [Related]
9. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Coller JK; Somogyi AA; Bochner F Br J Clin Pharmacol; 1999 Aug; 48(2):158-67. PubMed ID: 10417492 [TBL] [Abstract][Full Text] [Related]
10. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063 [TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Helsby NA; Ward SA; Howells RE; Breckenridge AM Br J Clin Pharmacol; 1990 Aug; 30(2):287-91. PubMed ID: 2206791 [TBL] [Abstract][Full Text] [Related]
12. The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism. Kortunay S; Basci NE; Bozkurt A; Isimer A; Sayal A; Kayaalp SO Eur J Clin Pharmacol; 1997; 53(3-4):261-4. PubMed ID: 9476042 [TBL] [Abstract][Full Text] [Related]
13. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259 [TBL] [Abstract][Full Text] [Related]
14. The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Wright JD; Helsby NA; Ward SA Br J Clin Pharmacol; 1995 Apr; 39(4):441-4. PubMed ID: 7640152 [TBL] [Abstract][Full Text] [Related]
15. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. Kaneko A; Bergqvist Y; Takechi M; Kalkoa M; Kaneko O; Kobayakawa T; Ishizaki T; Björkman A J Infect Dis; 1999 Apr; 179(4):974-9. PubMed ID: 10068594 [TBL] [Abstract][Full Text] [Related]
16. No correlation between side-chain of propranolol oxidation and S-mephenytoin 4'-hydroxylase activity. Xie HG; Xu ZH; Huang SL; Liu JH; Wu JX; Jiang CH; Zhou HH Zhongguo Yao Li Xue Bao; 1997 May; 18(3):216-8. PubMed ID: 10072936 [TBL] [Abstract][Full Text] [Related]
17. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Birkett DJ; Rees D; Andersson T; Gonzalez FJ; Miners JO; Veronese ME Br J Clin Pharmacol; 1994 May; 37(5):413-20. PubMed ID: 8054246 [TBL] [Abstract][Full Text] [Related]
18. Polymorphic oxidative metabolism of proguanil in a Nigerian population. Bolaji OO; Sadare IO; Babalola CP; Ogunbona FA Eur J Clin Pharmacol; 2002 Nov; 58(8):543-5. PubMed ID: 12451432 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Somogyi AA; Reinhard HA; Bochner F Br J Clin Pharmacol; 1996 Mar; 41(3):175-9. PubMed ID: 8866915 [TBL] [Abstract][Full Text] [Related]
20. Hepatic cytochrome P450 CYP2C activity in psoriasis: studies using proguanil as a probe compound. Helsby NA; Ward SA; Parslew RA; Friedmann PS; Rhodes LE Acta Derm Venereol; 1998 Mar; 78(2):81-3. PubMed ID: 9534880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]